Purus Wealth Management LLC Acquires Shares of 3,318 Solventum Corporation $SOLV

Key Points

• Purus Wealth Management bought a new stake of 3,318 shares in Solventum (NYSE:SOLV) in Q2, valued at approximately $252,000.
• Other institutions also adjusted positions — notably Jennison Associates opened a new stake worth about $3.08 million and South Dakota Investment Council increased its holdings to 255,625 shares (≈$19.4 million).
• Analyst consensus is a Hold with an average target of $85.56; Solventum recently beat quarterly EPS estimates ($1.50 vs. $1.43) and set FY2025 guidance of 5.98–6.08 EPS, while the stock trades around $76 with a P/E of 8.76.

Purus Wealth Management LLC bought a new stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,318 shares of the company's stock, valued at approximately $252,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SOLV. Nisa Investment Advisors LLC raised its holdings in Solventum by 0.6% during the 2nd quarter. Nisa Investment Advisors LLC now owns 33,974 shares of the company's stock valued at $2,577,000 after acquiring an additional 210 shares during the period. South Dakota Investment Council lifted its holdings in Solventum by 3.6% during the 2nd quarter. South Dakota Investment Council now owns 255,625 shares of the company's stock worth $19,387,000 after purchasing an additional 8,960 shares in the last quarter. Chelsea Counsel Co. boosted its stake in Solventum by 720.7% in the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company's stock worth $804,000 after purchasing an additional 9,304 shares during the period. ST Germain D J Co. Inc. grew its holdings in Solventum by 84.6% during the 2nd quarter. ST Germain D J Co. Inc. now owns 825 shares of the company's stock valued at $63,000 after buying an additional 378 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in Solventum during the 2nd quarter worth approximately $3,076,000.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several recent analyst reports. UBS Group raised their price target on Solventum from $77.00 to $79.00 and gave the company a "neutral" rating in a report on Monday, November 10th. Jefferies Financial Group initiated coverage on shares of Solventum in a research report on Thursday, September 11th. They issued a "hold" rating and a $80.00 price objective on the stock. Wells Fargo & Company lifted their target price on shares of Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a research report on Monday, September 15th. Zacks Research raised shares of Solventum from a "hold" rating to a "strong-buy" rating in a report on Monday, September 15th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Solventum in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Solventum has a consensus rating of "Hold" and an average target price of $85.56.

Solventum Stock Up 0.5%

Shares of NYSE SOLV opened at $76.05 on Tuesday. The company has a market cap of $13.19 billion, a price-to-earnings ratio of 8.76, a PEG ratio of 2.93 and a beta of 0.49. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03. The firm's fifty day moving average is $72.17 and its 200 day moving average is $72.82. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping analysts' consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.05 billion. During the same period in the prior year, the business posted $1.64 earnings per share. Solventum's revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.